Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD)
文献类型：期刊论文
| 作者 | Zhou, Gaoli2,3; Xing, Ronge3,5; Wang, Zongji1; Li, Rongfeng3,5; Liu, Song3,5; Li, Hang3,4; Li, Guantian3,4 |
| 刊名 | CARBOHYDRATE POLYMERS
 |
| 出版日期 | 2026-03-01 |
| 卷号 | 375页码:17 |
| 关键词 | Metabolic disorders Chitin Steatohepatitis Obesity Crustacean |
| ISSN号 | 0144-8617 |
| DOI | 10.1016/j.carbpol.2025.124737 |
| 通讯作者 | Li, Hang(hangli@qdio.ac.cn) ; Li, Guantian(guantianli@qdio.ac.cn) |
| 英文摘要 | Metabolic dysfunction-associated steatotic liver disease (MASLD), previously called metabolic dysfunctionassociated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD), has emerged as a leading cause of chronic liver injury worldwide, driven by insulin resistance, oxidative stress, inflammation, and gut dysbiosis. Current pharmacotherapies remain limited in efficacy and safety, underscoring the need for alternative strategies. Chitosan and chito-oligosaccharides represent promising candidates owing to their multifunctional bioactivities and excellent safety profiles. Evidence from cellular, animal, and preliminary clinical studies indicates that these compounds exert protective effects through coordinated modulation of multiple pathophysiological pathways. They enhance intestinal barrier function and promote the growth of beneficial gut microbiota, leading to reduced lipopolysaccharide translocation and improved hepatic inflammation via gut-liver axis regulation. Simultaneously, chitosan and chito-oligosaccharides activate AMP-activated protein kinase and PPAR alpha signaling, inhibit lipogenic enzymes, and upregulate fatty acid oxidation, thereby restoring lipid homeostasis. Their antioxidant capacity is mediated through nuclear factor erythroid 2-related factor 2 activation, while inflammatory cascades involving NF-kappa B and cytokine overproduction are suppressed. Collectively, these findings position chitosan and chito-oligosaccharides as sustainable therapeutics targeting multiple metabolic and inflammatory pathways in MASLD. |
| WOS关键词 | HIGH-FAT DIET ; LIPID-ACCUMULATION ; SUPPLEMENTATION ; INHIBITION ; CHITOOLIGOSACCHARIDES ; GLUCOSAMINE ; WEIGHT ; INJURY ; NAFLD ; MICE |
| 资助项目 | Taishan Scholars Program[tsqn202306285] ; Shandong Excellent Young Scientists Fund Program (Overseas)[2024HWYQ-077] |
| WOS研究方向 | Chemistry ; Polymer Science |
| 语种 | 英语 |
| WOS记录号 | WOS:001636500500002 |
| 出版者 | ELSEVIER SCI LTD |
| 源URL | [http://ir.qdio.ac.cn/handle/337002/204433]  |
| 专题 | 海洋研究所_实验海洋生物学重点实验室 |
| 通讯作者 | Li, Hang; Li, Guantian |
| 作者单位 | 1.Linyi Univ, Regenerat Med Inst, Linyi 276000, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Chinese Acad Sci, Inst Oceanol, Lab Expt Marine Biol, Qingdao 266000, Peoples R China 4.Qingdao Marine Sci & Technol Ctr, Lab Marine Biol & Biotechnol, Qingdao 266237, Peoples R China 5.Qingdao Marine Sci & Technol Ctr, Lab Marine Drugs & Bioprod, Qingdao 266237, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhou, Gaoli,Xing, Ronge,Wang, Zongji,et al. Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. CARBOHYDRATE POLYMERS,2026,375:17. |
| APA | Zhou, Gaoli.,Xing, Ronge.,Wang, Zongji.,Li, Rongfeng.,Liu, Song.,...&Li, Guantian.(2026).Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD).CARBOHYDRATE POLYMERS,375,17. |
| MLA | Zhou, Gaoli,et al."Chitosan and chito-oligosaccharides as multifunctional therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD)".CARBOHYDRATE POLYMERS 375(2026):17. |
入库方式： OAI收割
来源：海洋研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。